Clinical trials: Pharmacogenetics
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00398645
- Testing
- GW685698X 200mcg,GW685698X 200mcg and 400mcg
- Where
- 82 sites in United States, Australia and 14 more
- Volunteers
- 648 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major
Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients
This study evaluates the efficacy of NEUROPHARMAGEN pharmacogenetic test in the selection of the pharmacological treatments for patients with Major Depressive Disorder (MDD), both with and without psychiatric comorbidities.
- Trial name
- NCT02529462
- Testing
- NEUROPHARMAGEN-Guided Treatment, Treatment As Usual
- Where
- 12 sites in Spain
- Volunteers
- 521 people
- Sponsor
- AB Biotics, SA
Hypertension
Antihypertensive Response to Losartan and Genetic Polymorphisms
The purpose of this study is to evaluate the antihypertensive response of treatment with losartan with reference to genetic polymorphisms.
- Trial name
- NCT00617877
- Testing
- losartan potassium, Comparator: Hydrochlorothiazide
- Volunteers
- 800 people
- Sponsor
- Merck Sharp & Dohme LLC
Systemic Lupus Erythematosus
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.
- Trial name
- NCT02185040
- Testing
- CC-220
- Where
- 35 sites in United States
- Volunteers
- 42 people
- Sponsor
- Celgene
HIV Infection
HLA-B*5701 And Hypersensitivity To Abacavir
This retrospective case-control study is being conducted to estimate the sensitivity of the pharmacogenetic marker, HLA-B*5701 for hypersensitivity to abacavir (ABC HSR).
- Trial name
- NCT00373945
- Testing
- Observational Study
- Where
- 55 sites in United States
- Volunteers
- 280 people
- Sponsor
- GlaxoSmithKline
Asthma
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.
This is a Phase III, multicenter, randomized, double-blind, stratified, parallel-group study with three active comparators in subjects with moderate to severe persistent asthma.
- Trial name
- NCT01686633
- Testing
- Fluticasone Furoate/ Vilanterol 200/25 mcg, Fluticasone Furoate/ Vilanterol 100/25 mcg, Fluticasone Furoate 100 mcg
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,040 people
- Sponsor
- GlaxoSmithKline
Hypertension
Association Between Genetic Algorithm to Predict Hypertension Therapy and Response to Treatment
To assess the effectiveness of the use of a patient's genes to predict which hypertension therapy is successful
- Trial name
- NCT03292900
- Where
- United States
- Volunteers
- 758 people
- Sponsor
- Geneticure, LLC
Current or Recent History of Atrial Fibrillation
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who…
- Trial name
- GENETIC-AF (NCT01970501)
- Testing
- bucindolol hydrochloride, metoprolol succinate
- Where
- 97 sites in United States, Canada and 4 more
- Volunteers
- 267 people
- Sponsor
- ARCA Biopharma, Inc.
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00603278
- Testing
- GW685698X
- Where
- 155 sites in United States, Canada and 11 more
- Volunteers
- 622 people
- Sponsor
- GlaxoSmithKline
Depression, Anxiety
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial.
- Trial name
- UHS (NCT01632267)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Assurex Health Inc.
Pharmacogenetic Testing, Elderly
Pharmacist-led Pharmacogenomic Clinical Service Within the Program of All-inclusive Care for the Elderly
Pharmacist-led pharmacogenomics (PGx) clinical services and medication safety reviews are currently being offered to PACE organizations under the direction of licensed healthcare prescribers by CareKinesis d/b/a Tabula Rasa…
- Conditions
- Pharmacogenetic Testing, Elderly, Opioid Use, Pain
- Trial name
- NCT04971902
- Testing
- Pharmacogenetic Test
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Tabula Rasa HealthCare
Lumbar Spine Stenosis, Lumbar Spine Degeneration
OpalGenix- Personalized Postoperative Pain Management Following Lumbar Spinal Fusion and Decompression Surgery in Adults
The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research.
- Trial name
- NCT05452694
- Where
- 3 sites in United States
- Volunteers
- 235 people
- Sponsor
- OpalGenix, Inc
Relapsing Multiple Sclerosis
The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial
This study, REbif® vs Glatiramer acetate in relapsing multiple sclerosis (MS) disease - pharmacogenetic(s) (REGARD-PGx) is a single blood sampling exploratory pharmacogenetic study of the REGARD trial.
- Trial name
- REGARD-PGx (NCT01034579)
- Testing
- Blood sampling
- Where
- United States
- Volunteers
- 324 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)
This study, PRISMS-15 is a single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial.
- Trial name
- PRISMS-15 (NCT01034644)
- Where
- Switzerland
- Volunteers
- 290 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Acute Pain, Surgery
Prospective Observational Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Patients Undergoing Elective Surgical Procedures
The purpose of this study is to evaluate the effect of pharmacogenetics (PGx) guided treatment when implemented into the pre-operative process for patients undergoing bowel surgery, major urologic procedure, or major ventral…
- Trial name
- NCT02605343
- Testing
- NeuroIDgenetix Test Panel
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- AltheaDx
HIV Infection
Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity
Study to evaluate the utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity (ABC HSR) in 1800 previously ABC-naive adults with HIV-1 from Europe, Australia and other countries as applicable.
- Trial name
- NCT00340080
- Testing
- Abacavir
- Where
- 254 sites in Australia, Austria and 17 more
- Volunteers
- 1,806 people
- Sponsor
- GlaxoSmithKline
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Atrial Fibrillation, Deep Vein Thrombosis
Association Between Genetic Variant Scores and Warfarin Effect
Study objective is to determine whether there is an association between genetic variant risk scores and clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ≥…
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Intracardiac Thrombus, Pulmonary Embolism
- Trial name
- AWARE1 (NCT03894878)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Cipherome, Inc.
Schizophrenia, Schizoaffective Disorder
A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses
An individual's genetic make-up is known to determine their response to antipsychotic medication. Genetic markers that determine efficacy and side effects of medication may be identified and used to predict treatment outcome.
- Trial name
- NCT00701753
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- TheraGenetics Limited
Depression, Anxiety
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy
A randomized controlled trial comparing pharmacogenomic guided versus standard pharmacist care to optimize antidepressant drug therapy.
- Conditions
- Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder
- Trial name
- NCT03591224
- Testing
- Pharmacogenomic Testing, Pharmacist Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- John Papastergiou Pharmacy Ltd